Mycobutin (Rifabutin)

Rifabutin inhibits the bacterial DNA‑dependent RNA polymerase by binding to its beta subunit. This blocks the initiation of RNA synthesis, halting transcription of essential genes and leading to the death of susceptible mycobacterial cells.

The specific dose of Mycobutin is determined by the prescribing clinician based on the indication, patient weight, renal and hepatic function, and any concomitant medications. Dosage regimens are individualized and should follow the prescriber’s instructions.

Safety data for rifabutin in pregnancy and lactation are limited. It should only be used when the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order Mycobutin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Rifabutin shares the core mechanism of RNA polymerase inhibition with other rifamycins such as rifampicin, but it generally has a longer half‑life and a lower propensity for inducing certain cytochrome P450 enzymes, which can result in fewer drug‑interaction concerns in some regimens.

Mycobutin should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in humid or excessively hot environments.

Mycobutin is taken orally, usually with food or a glass of water to improve tolerance. The exact administration schedule—such as once daily or multiple times per day—depends on the prescriber’s regimen and the clinical indication.

Serious adverse events include neutropenia, hepatotoxicity, severe hypersensitivity reactions, thrombocytopenia, hemolytic anemia, and interstitial pneumonitis. Patients should be monitored regularly for signs of infection, liver dysfunction, blood count changes, or respiratory symptoms.

Mycobutin is contraindicated in individuals with known hypersensitivity to rifabutin or any rifamycin class. Caution is also advised for patients with severe hepatic impairment, uncontrolled immunodeficiency, or those taking medications that may cause dangerous interactions without appropriate monitoring.